Article

AMD drug's phase I results to be presented at AAO

A biotechnology company will be presenting its ASaP phase I clinical data for its leading drug candidate (POT-4, Potentia Pharmaceuticals) during Retina Subspecialty Day at the annual meeting of the American Academy of Ophthalmology in Atlanta Nov. 7.

Lousiville, KY-A biotechnology company will be presenting its ASaP phase I clinical data for its leading drug candidate (POT-4, Potentia Pharmaceuticals) during Retina Subspecialty Day at the annual meeting of the American Academy of Ophthalmology (AAO) in Atlanta Nov. 7.

"[This drug] is the first of several complement inhibitors that will ultimately be tested in macular degeneration. The role of complement in this disease was established in 2005 as the first breakthrough discovery resulting directly from the human genome project,” said Cedric Francois, president and chief executive officer of Potentia Pharmaceuticals. “If complement inhibition is successful at treating macular degeneration, it would be the first of hopefully many new drugs born out of the human genome project, and usher in an era of improved healthcare for millions of patients."

Philip J. Rosenfeld, MD, PhD, professor of ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, and a clinical investigator in the study, will present the data.

The complement inhibitor shuts down the complement activation cascade that otherwise could lead to local inflammation, tissue damage, and upregulation of angiogenic factors such as vascular endothelial growth factor in the eye. Based on this mechanism of action, POT-4 holds the potential to be effective against both the dry and wet forms of age-related macular degeneration.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
© 2025 MJH Life Sciences

All rights reserved.